ESOPHAGEAL SQUAMOUS CELL CARCINOMA

This study aimed to test a new drug (S095033) combined with chemotherapy (paclitaxel) in people with advanced or spreading esophageal cancer. The goal was to see if the combination was safe and could shrink tumors. However, the trial was withdrawn before enrolling any participant…

This study is testing whether adding the drug serplulimab to standard chemotherapy before surgery can help people with esophageal cancer. The goal is to see if this combination can shrink tumors more effectively and lower the chance of the cancer coming back. About 48 adults with…

This phase 3 study tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced esophageal cancer that has returned or spread. It is for patients whose cancer did not respond to or stopped responding to initial treatment with immunotherapy and platinum-…

This study tests whether adding two targeted drugs (nimotuzumab and camrelizumab) to standard chemotherapy before surgery can improve outcomes for people with locally advanced esophageal cancer. About 48 adults aged 18-70 with resectable tumors will be randomly assigned to receiv…

This study tests whether adding tiragolumab to atezolizumab can help prevent esophageal cancer from growing back after initial chemoradiotherapy. About 760 adults with advanced esophageal cancer that cannot be surgically removed will receive either the drug combination, atezolizu…

This study tests whether adding an experimental drug called LBL-007 to standard chemotherapy and immunotherapy can better shrink or control advanced esophageal cancer. About 118 adults with inoperable or spread esophageal squamous cell carcinoma will receive either the triple com…

This study tested whether adding two drugs, nivolumab and cetuximab, to standard chemoradiation helps shrink advanced esophageal cancer before surgery. Twelve people who had not been treated before took part. The goal was to see if the cancer completely disappeared after treatmen…

This study tests an experimental drug called MCLA-129 in people with advanced non-small cell lung cancer and other solid tumors that have stopped responding to standard treatments. The drug is a bispecific antibody designed to block two cancer-related proteins (EGFR and c-MET) at…

This study tests whether adding the drug durvalumab to standard chemotherapy and radiation can help people with advanced esophageal cancer that cannot be removed by surgery. About 640 adults with this type of cancer will receive either durvalumab or a placebo alongside their canc…

This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to a medium-dose three-drug chemotherapy and radiation can better control advanced esophageal cancer. About 50 participants will receive the treatment over a year, including probiotics and an immune booster. T…

This study looks at whether adding immunotherapy (tislelizumab) to chemotherapy can help high-risk patients with esophageal cancer who still have cancer after standard chemoradiation. About 80 participants will receive the combination, then surgery, and possibly more treatment ba…

This early-phase trial tests whether combining two drugs, camrelizumab and palbociclib, is safe and feasible for patients with a type of esophageal cancer that can be surgically removed. The drugs are given before surgery to try to shrink the tumor. The study involves 6 participa…

This study tests whether adding the drug apatinib to standard chemotherapy, immunotherapy, and radiation helps control advanced esophageal cancer that cannot be surgically removed. About 170 adults with this type of cancer will be randomly assigned to receive the standard treatme…

This study tests a treatment plan for people with esophageal cancer that hasn't spread. Before surgery, patients receive chemotherapy, radiation, and two immunotherapy drugs (pembrolizumab and lenvatinib) to shrink tumors and boost the immune system's attack on cancer. The goal i…

This early-phase study tests an experimental drug called ABBV-400 in about 302 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The main goals are to check safety, side effects, and whether the drug shrinks tumors. Participants receive …

This early-stage study tests a new drug, RO7247669, that works like a double-pronged key to help the immune system attack cancer cells. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options will r…